Ibnsina Pharma (EGX: ISPH)
Egypt
· Delayed Price · Currency is EGP 6.42
-0.09 (-1.38%)
At close: Dec 3, 2024
Ibnsina Pharma Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 446.14 | 213.66 | 172.58 | 314.73 | 224.66 | 328.77 | Upgrade
|
| Depreciation & Amortization | 224.52 | 184.22 | 182.53 | 175.34 | 129.21 | 84.96 | Upgrade
|
| Other Amortization | 19.46 | 6.57 | 5.64 | 2.75 | 1.91 | 1.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.18 | -1.39 | -1.21 | -4.25 | -1.94 | -1.06 | Upgrade
|
| Loss (Gain) on Equity Investments | 1.42 | 1.13 | - | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 140.82 | 83.85 | 65.53 | -45.13 | 24.34 | 14.52 | Upgrade
|
| Other Operating Activities | 326.1 | 173.02 | -41.75 | 88.58 | -13.32 | 96.31 | Upgrade
|
| Change in Accounts Receivable | -5,318 | -4,068 | -85.2 | -1,284 | -410.14 | -916.83 | Upgrade
|
| Change in Inventory | -1,996 | -671.73 | -400.14 | -194.15 | -348.14 | -309.85 | Upgrade
|
| Change in Accounts Payable | 7,078 | 4,386 | 558.68 | 697.3 | 751.2 | 899.17 | Upgrade
|
| Change in Other Net Operating Assets | -212.25 | -181.75 | -94.79 | -91.78 | -105.91 | -222.08 | Upgrade
|
| Operating Cash Flow | 710.09 | 125.81 | 361.88 | -340.43 | 251.87 | -24.83 | Upgrade
|
| Operating Cash Flow Growth | 248.66% | -65.23% | - | - | - | - | Upgrade
|
| Capital Expenditures | -176.61 | -354.04 | -798.46 | -147.53 | -230.13 | -355.24 | Upgrade
|
| Sale of Property, Plant & Equipment | 36.42 | 82.45 | 50.45 | 16.01 | 2.42 | 1.77 | Upgrade
|
| Sale (Purchase) of Intangibles | -17.76 | -8.23 | -26.18 | -11.15 | -0.32 | -4.22 | Upgrade
|
| Other Investing Activities | -1.98 | - | -601.86 | - | - | -36.99 | Upgrade
|
| Investing Cash Flow | -159.93 | -279.82 | -1,376 | -142.67 | -228.03 | -394.68 | Upgrade
|
| Short-Term Debt Issued | - | 875.52 | 721.63 | 960.4 | 330.99 | 211.82 | Upgrade
|
| Long-Term Debt Issued | - | 362.57 | 712.39 | - | - | 325.46 | Upgrade
|
| Total Debt Issued | 663.56 | 1,238 | 1,434 | 960.4 | 330.99 | 537.28 | Upgrade
|
| Long-Term Debt Repaid | - | -471.63 | -21.53 | -250.65 | -120.39 | -24.81 | Upgrade
|
| Total Debt Repaid | -997.5 | -471.63 | -21.53 | -250.65 | -120.39 | -24.81 | Upgrade
|
| Net Debt Issued (Repaid) | -333.95 | 766.46 | 1,412 | 709.75 | 210.6 | 512.47 | Upgrade
|
| Issuance of Common Stock | - | - | 0.49 | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | -185.74 | -14.4 | - | - | Upgrade
|
| Common Dividends Paid | -25.62 | -22.94 | -140.4 | -14.59 | -82.02 | -71.11 | Upgrade
|
| Financing Cash Flow | -359.56 | 743.52 | 1,087 | 680.77 | 128.58 | 441.36 | Upgrade
|
| Net Cash Flow | 190.6 | 589.52 | 72.67 | 197.66 | 152.42 | 21.84 | Upgrade
|
| Free Cash Flow | 533.48 | -228.23 | -436.58 | -487.96 | 21.75 | -380.08 | Upgrade
|
| Free Cash Flow Margin | 1.10% | -0.67% | -1.96% | -2.25% | 0.12% | -2.29% | Upgrade
|
| Free Cash Flow Per Share | 0.53 | -0.23 | -0.43 | -0.37 | 0.02 | -0.34 | Upgrade
|
| Cash Interest Paid | 1,258 | 929.98 | 481.52 | 281.54 | 250.34 | 258.07 | Upgrade
|
| Cash Income Tax Paid | - | - | - | 76.32 | 85.85 | - | Upgrade
|
| Levered Free Cash Flow | -3,620 | -2,733 | -1,500 | -617.13 | -1,068 | -757.44 | Upgrade
|
| Unlevered Free Cash Flow | -2,674 | -2,080 | -1,201 | -439.52 | -908.37 | -599.63 | Upgrade
|
| Change in Net Working Capital | 3,866 | 2,620 | 861.91 | 876.02 | 1,114 | 734.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.